Abstract
Methods are directed to modifying an HLA allele associated with an autoimmune disease. In one example, a method includes modifying an HLA allele such that the modified HLA allele encodes a non-polar amino acid instead of a target amino acid at an anchor position. A modified HLA protein encoded by the modified HLA allele can possess altered binding affinity for at least one self-peptide. In certain embodiments, the target amino acid is at anchor position 82 in a DRB1 or DQB1 allele or at position 80 in a DPB1 allele.
Full Text
What is claimed is:
Methods are directed to modifying an HLA allele associated with an autoimmune disease. In one example, a method includes modifying an HLA allele such that the modified HLA allele encodes a non-polar amino acid instead of a target amino acid at an anchor position. A modified HLA protein encoded by the modified HLA allele can possess altered binding affinity for at least one self-peptide. In certain embodiments, the target amino acid is at anchor position 82 in a DRB1 or DQB1 allele or at position 80 in a DPB1 allele.
Timeline
Filed
04/28/2026Published
08/27/2026Granted
Not AvailableIPC Codes(8)
C07K 14/705:Receptors; Cell surface antigens; Cell surface determinants
A61K 35/28:Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 38/00:Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K 31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K 31/00; ergoline-based peptides A61K 31/48; containing macromolecular compounds having statistically distributed amino acid units A61K 31/74; medicinal preparations containing antigens or antibodies A61K 39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K 47/00)